Subject: CSD Canada - Best-in-Class Canadian Pharmaceutical Market Research Data (Global data too!) Hi there, Please review this presentation if you are involved in sourcing market research, doing business planning or just simply interested in a great market research vendor! Cegedim Strategic Data (CSD) provides the most up-to-date, cost-effective audit of pharmaceutical promotional, messaging and patient data in Canada. With ongoing critical information at your fingertips - such as your sales reps’ share of voice (SOV) and how many of your details generate prescriptions - CSD provides you a view of your marketplace you simply can’t get elsewhere. Over the next few weeks, CSD will be offering on-site presentations to bring clients up-to-date on our methodologies, data metrics, software, reporting and new services. If you would like to book an on-site presentation to your team, please reply to vernon.mascarenhas@cegedim.com or call 416-335-3545. Yours, Vern Vernon Mascarenhas

1. The Power of Strategic Integration Cegedim Strategic Data (CSD) Market Research Capabilities Overview CEGEDIM © copyright 2009 – this document should not be distributed without CEGEDIM authorisation

2. CONTENTS CEGEDIM GROUP AND CSD PHARMACEUTICAL MARKET RESEARCH Promotional Data Communication DATA Patient DATA Custom Primary Market Research

4. Physician Connect™REVENUE2008 FOUNDED WORKFORCE € 849 M / $CAD 1.4 B 1969 8,200 EURONEXT PARIS MARKETS since 1995 80 countries Primary & Secondary MARKET RESEARCH CRM systems EMR Electronic Medical Records HEALTHCARE PROFESSIONALS

5. CSD : 36 Operations Covering Markets in 60 Countries Top 5 Europe Americas Asia Pacific Japan Australia China India Korea Malaysia Taiwan France Germany Italy Spain UK USA Canada México Argentina Brazil Colombia Nordics Central/Eastern Europe Other Europe Denmark Finland Norway Sweden Austria Czech Republic Poland Romania Russia Slovakia Belgium Ireland Luxemburg Netherlands Southern Europe Africa Greece Portugal Turkey Algeria Morocco Tunisia

6. CSD : INTEGRATED HEALTHCARE RESEARCH … Devoted to the Pharmaceutical Industry

8. Main messages by brand

9. Most/least impactful messages

10. Competitive claims

11. Impact on Rx Intention

12. Competitive Data

13. Prescriptions by patient type

15. Market shares & evolution

16. Competitive Data

17. Share of Voice

18. Rep Equivalents

19. Detailing information

20. Industry-wide Audits

21. GPs, Specs, Pharmacists…and CUSTOM Primary Market Research

22. Example of studies for a Biopharmaceutical Leader… CSD is probably working with your global affiliates STUDY TYPES REGIONS THERAPEUTIC AREAS OSTEOPOROSIS BRAND EQUITY NORTH AMERICA ONCOLOGY PRE-LAUNCH LANDSCAPING CANADA RHEUMATOID ARTHRITIS USAGE AND AWARENESS USA KIDNEY DISEASE MESSAGE RECALL & TRACKING TOP EUROPEAN PATIENT SEGMENTATION FRANCE POSITIONING GERMANY PROMOTIONAL DATA SWEDEN COMMUNICATION FOLLOW-UP UK PATIENT DATA ITALY BRIC COUNTRIES RUSSIA 7 CEGEDIM © copyright 2009 – this document should not be distributed without CEGEDIM authorisation

24. USA

25. France

30. CONTENTS CEGEDIM GROUP AND CSD Promotional Data Communication DATA Patient DATA Custom Primary Market Research

31. CSD Promotional Tracking Studies by Channel 11

32. CSD Promotional Tracking Studies by Channel ACTUAL PROMOTIONAL Data for the OSTEOPOROSIS Market

33. 13

34. K$ Promotional Investment (% Share) – All Channels GPs, Specialists & Pharmacists: 14

35. K$ Total Detailing Investment – S.O.I GPs, Specialists & Pharmacists: 15

36. Promotional Mix by ProductQ1-2009 vs Q1-2008 GPs, Specialists & Pharmacists: K$ Q1-2009 K$ Q1-2008 16

37. 17

38. GP and Specialist Detailing SOV by Product : Q1-2009 18

39. GP Details and SOV by Product : Q1 2008 to Q1 2009 Details 19

40. Specialist Details and SOV by Product : Q1 2008 to Q1 2009 Details 20

41. CONTENTS CEGEDIM GROUP AND CSD Promotional Data Communication DATA Patient DATA Custom Primary Market Research

42. CSD Communication – Message Tracking Studies (MTS) 22

43. CSD Communication – Message Tracking Studies (MTS) ACTUAL COMMUNICATION Data for the DIABETES Market

44. Ongoing Data Available for Osteoporosis and Other Markets COMMUNICATION DATA Message Tracking Study (MTS) Recoded Verbatim Messages Diabetes Market Canada Focus on Five Key Brands Q4/2008 throughQ1/2009 24

45. 25

46. Message Tracking Study (MTS) : Focus on Five Brands* *Based on messages recalled verbatim by representative panel of GPs, Specialists & Pharmacists as a result of detailing efforts betweenOct 2008 and Mar 2009. Per CSD Promotion Database. 26

47. Communication Summary – Key Messages Recalled GPs, Specialists & Pharmacists: Q4/08 through Q1/09 27

48. Key messages by Category, by Brand n=40 n=113 n=92 n=163 n=36 n=456 Notes: n : number of messages. 1 raw Verbatim could have more than 1 message. OAD : total class of Oral Anti-Diabetic. EBM : Evidence-based medicine. SEs = Side Effects, Gen. Diab. Mgmt. = Other General comments related to management of Diabetes, not otherwise classified GPs, Specialists & Pharmacists: Q4/08 through Q1/09 28

49. Interest in the Detail by Brand n=83 n=28 n=78 n=114 n=34 n=347 GPs, Specialists & Pharmacists: Q4/08 through Q1/09 Notes: n : number of rawverbatims. 1 raw Verbatim could have more than 1 message. OAD : total class of Oral Anti-Diabetic. 29

50. % of Interesting Verbatim 47% 36% 35% 32% 32% Product Details Generating the Most Interest : Key Messages Most Interest JANUVIA New treatment : inhibitor of DPP-4 acts on intestinal Incretins stimulating insulin secretion after a meal and protects beta-cell of the pancreas Reliable glucose lowering / reduces HbA1c 1-5% Well tolerated / Less side effects / Weight neutral / Less weight gain Less hypoglycaemia than other SULFONYLUREA For patient not controlled with METFORMIN and SULFONYLUREA Effective for type 2 diabetes with METFORMIN AVANDIA Safety of AVANDIA based on study / Controversy on cardiovascular risk Diabetis2008 Canadian guidelines – Studies : ADOPT & MIRACLE. Efficacy in BS / HbA1c lowering ReducesInsulinresistance Use as second line therapy DIAMICRON Price of DIAMICRON MR has been reduced / no reason to switch to generics 24 hours BS control / Improvesdiabetic glucose control Fully covered by ODB plan Less hypoglyceamia especially in elderly GLUMETZA New 1000mg dosing – Improved compliance with once daily dosing Long acting METFORMIN AVANDAMET Improved compliance with combination pill / Once a day combo with METFORMIN Best glycemic control / decreases HbA1c Presentation of new GUIDELINES for type 2 diabetis GPs, Specialists & Pharmacists: Q4/08 through Q1/09 Least Interest 30

51. Future Prescribing (Rx) Intention by Brand n=83 n=28 n=78 n=114 n=34 n=347 GPs, Specialists & Pharmacists: Q4/08 through Q1/09 Notes: n : number of rawverbatims. 1 raw Verbatim could have more than 1 message. OAD : total class of Oral Anti-Diabetic. 31

52. 55% 41% 32% 29% 22% % of Verbatim with Rx Intention=Increase Brands with Greatest Increase in Intent to Rx: Key Messages GreatestIncrease in Intent to Prescribe JANUVIA New alternative in diabetes type II care / first DPP4 Blocks the effect of Incretin-increases GIP (gastric inhibitory peptide) and GLP-1 (glucagon-like peptide-1) Safer in regards hypoglycemia & weight gain than other hypoglycemic classes Less hypoglycaemia than other SULFONYLUREA Weight neutral / Less weight gain / less side effects Treatment accurate with METFORMIN / Add-On therapy RAMQ exception drug list AVANDAMET Improved compliance with combination pill / Once a day combo with METFORMIN Sustained effect on blood sugar GLUMETZA Long acting METFORMIN Fewer side effects Improved compliance with once-a-day dosing DIAMICRON Price of DIAMICRON MR has been reduced / no reason to switch to generics Add-on with METFORMIN Less side effects than other SULFONYLUREAS / Safe on kidney AVANDIA Product on Canadian Diabetes Association Guidelines Safety / new studies show AVANDIA is not harmful / RECORD soon available For reducing INSULIN resistance GPs, Specialists & Pharmacists: Q4/08 through Q1/09 Least Increase in Intent to Prescribe 32

53. n =163 n=4 n=6 n=4 n=42 n=29 n=38 n=37 n=3 Details that lead to an Increase in the Intent to Prescribe JANUVIA GPs, Specialists & Pharmacists: Q4/08 through Q1/09 n : number of messages. Note : 1 raw Verbatim could have more than 1 message 33

54. Details that lead to an Increase in the Intent to prescribe n=40 n=5 n=2 AVANDAMET n=8 n=7 n=6 n=9 n=1 n=2 GPs, Specialists & Pharmacists: Q4/08 through Q1/09 n : number of messages. Note : 1 raw Verbatim could have more than 1 message 34

55. Messages well-received by Physician Segment: DIAMICRON MR Current Habit Future Intent 35

56. GPs, Specialists & Pharmacists: Q4/08 through Q1/09 Arguments messages of <Client Molecule> n : number of messages. Note : 1 raw Verbatim could have more than 1 message 36

57. GPs, Specialists & Pharmacists: Q4/08 through Q1/09 Arguments messages of <Client Molecule> n : number of messages. Note : 1 raw Verbatim could have more than 1 message 37

58. GPs, Specialists & Pharmacists: Q4/08 through Q1/09 Arguments messages of <Client Molecule> n : number of messages. Note : 1 raw Verbatim could have more than 1 message 38

59. CONTENTS CEGEDIM GROUP AND CSD Promotional Data Communication DATA Patient DATA Custom Primary Market Research

60. CSD Patient Diary Studies (PDS) 40

61. CSD Patient Diary Studies (PDS) ACTUAL Patient Data for the OSTEPOROSIS Market

62. What is a PDS (Patient Diary Study)? What is a PDS? The PDS is a tool thatmonitors the market. With a PDS we keep an eye on prescription share... The PDS is patient data provided by physicians for a given market. Main PDS Advantages 1 It’s not claims-based research…. It is REAL PATIENT CASE reporting 2 …it’s real It reaches GPs and SPECIALISTS PATIENT DATA! 3 It reaches COMMUNITY- and HOSPITAL- based doctors

63. What methodology is used for a PDS? Patient Inclusion Criteria (Actual Criteria for Current Diabetes PDS in Canada) What methodology is usedfor a PDS? PDS studies will follow the same patient inclusion criteria: The methodology is conceived to collect essential information on a significant number of patients per doctor, maximizing the sample. 1 Patient must be diagnosed as diabetic(either type 1 or 2) 2 Patient must be/have been Rxed for diabetes (either OAD or insulin) 1 2 3 A representative sample is recruited Analyses are presented in a complete report Physicians report on patient cases 43

64. PDS Workflow Sent web link PDS monitors prescribing behavior Consultation(Prior to study) Recruitment Prescription Physician Reporting Monitoring Doctors fulfilling the requirements are recruited by telephone Doctors see patients pertaining to the study Doctors have written a script for each patient they have seen Doctors have the option of the Internet or mail in which to fill out patient information Data collection, PDS analysis and result delivery 44

65. CURRENT DIABETES PDS PROJECT IN PROGRESS ORAL ANTI-DIABETIC (OAD) MARKET 45

66. All CSD Strengths Applied to PDS CSD Strengths 15 years managing medical databases Promotional database update through a medical diary by doctors measuring sale reps visits and therefore pharmaceutical investments. 1 Medical Database Experts CSD is the only marketing research company that possesses 3 medicaldatabases and has so for 15 years: Longitudinal patient database updated through a software of consultation management serving doctors and transmitting data to CSD. Promotional Data - CAM Patient Data - Thales Communication Data - ZOOM Communication database storing doctors’ message recall regarding all promoted products. PDS is the complementary database on patient information for specialists and hospital based doctors. 46

67. All CSD Strengths Applied to PDS CSD Strengths 3 2 Competitive Intelligence Provider Ad-hoc Studies Know-how CSD offers concerns on all aspects of the marketing mix of pharmaceutical companies: Promotional Investment Patient Information Communication Follow-up CSD has a wide coverage with branches in 58 countries enabling in house fieldwork with a global reach. 5 4 Epidemiologic Studies Producer IT Technology Developer CSD is respected for its strong knowledge in medical research, having produced many epidemiological studies with scientific value in many domains: As a branch of the Cegedim Group, CSD benefits from expertise in IT systems and info management. Prevalence calculation Joined population Economic studies 47

68. Osteoporosis Patient Diary Study : Overview OSTEOPOROSIS Targets, Recruiting and Representative SAMPLING of : GENERAL PRACTITIONERS RHEUMATOLOGISTS GYNAECOLOGISTS EVOLUTION OVER TIME …. OVER A PERIOD OF YOUR CHOICE Data Collection of Patient Cases (Electronic & Paper) QUARTERLY SNAP SHOT or 48

70. GENDER

71. BMI (HEIGHT/WEIGHT)

72. RACE

74. TYPE 1 DIABETES

75. RHEUMATOID ARTHRITIS

76. INFLAMMATORY BOWEL

77. UNTREATED HYPOGONADISM

79. THYROID DISORDERS

80. PROLONGED IMMOBILITY

81. MENOPAUSE

82. EATING DISORDERS

83. Anorexia nervosa

84. Bulimia

85. DRUGS

86. CORTICOSTEROIDS

87. THYROID HORMONES

88. SSRIs

89. BREAST CANCER

90. SEDENTARY LIFESTYLE

91. CHRONIC ALCOHOLISM

93. SPINE

94. HIP

95. WRIST49

97. OSTEO PDS: DynamicMarket: Share by Product: All Specs Actual Data provided to AmgenFrance

98. OSTEO PDS : FosamaxSwitches, New Starts by Specialty Actual Data provided to AmgenFrance

99. OSTEO PDS : Net DynamicMarket by Product over Time Actual Data provided to AmgenFrance

100. OSTEOPOROSIS PDS Objectives: Monitor your product in the Osteoporosis market and identify patient conditions under which it is prescribed Understand what proportion of the Dynamic Rx market your product owns : New Starts, Add-on Therapy, Net Switches, Switches to/from and Why Start looking at patient demographics/profiles to understand what are the attributes of patients receiving your product – and implement marketing actions to penetrate / defend as necessary Track prescribing patterns among PMO, RA, OA, AS and other patient types / indications as appropriate Measure Prescription Share : # of patients by class by brand Understand Market Size and Growth Identify Treatment Patterns by Complication, by Patient Profile

102. Vernon MASCARENHASBusiness Development Director Primary Market Research Specialist Vernon has 12+ years experience in the pharmaceutical industry on the client side and as a consultant. On the corporate side Vernon has delivered business results as a specialty sales rep, sales force operations manager and market research manager. On the consulting side as a marketing research consultant, Vernon has built a reputation by delivering results. His sales and marketing efforts have contributed to the successful launch of 20+ products in diverse therapeutic areas. George PANARITIS Direct, Primary Market Research George has more than 10 years experience in Market Research primarily in the healthcare industry. He is currently directing CSD’s Primary Market Research division by managing and supporting new and ongoing business/program development and sales initiatives. He leads the sales process in seeking out new opportunities and manages the market research production process. Donald DeGryse Field Research Operations Manager Donald DeGryse has over 10 years experience as an Operations Manager dedicated to market research processes. As result he excels in operational leadership, best practices, communication, coaching and motivational skills. His market research operations background is in the Pharmaceutical, Telecommunications and Marketing Services verticals. SamyDaoud Market Research Analyst Samy has over 6 years of analytical experience, having worked for various research companies in a variety of industries. Samy is replied upon as subject matter expert in statistics , analytics and data management. His educational background is in mathematics and statistics. APPENDIX A : CSD TEAM - Overview, Select Personnel 56

103. APPENDIX B : COMPANY OVERVIEW About Cegedim Group: Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, pharmaceutical companies, healthcare professionals and insurance companies. The world leader in pharmaceutical CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,200 people in more than 80 countries and generated revenue of €849 million in 2008. To learn more, please visit our website: www.cegedim.com About Cegedim Strategic Data (CSD): CSD is a leading Market Research company dedicated to the healthcare industry and operating in more than 58 countries. With over 35 years experience in the Pharmaceutical industry, CSD offers a comprehensive range of market research services and solutions to its customers, which include more than 50 global and 500 local Pharmaceutical companies. CSD integrates primary and secondary analyses with its medical expertise to meet its customer’s research needs. To learn more, please visit our website: www.cegedimstrategicdata.com 57

106. Finally, CSD assigns dedicated teams of healthcare researchers with the most salient experience to each project from beginning to end, so that the best thinking is brought to bear, a focused environment is created and to ensure the best, most timely feedback are gathered for our consultative approach ensuring a premium level of client service, meeting the objectives, and provide clear and insightful recommendations.58

107. CSD CONTACTS Vernon Mascarenhas Business Development Director Phone: 416-335-3545 / Cell: 647-998-8376 Email: vernon.mascarenhas@cegedim.com George PanaritisDirector, Primary Market Research Phone: 514-906-4604 / Cell: 514-827-2202 Email : george.panaritis@cegedim.com GwénaëlleDelpirou General Manager CSD Canada Phone : 514-906-4601 / Cell: 514-629-7122 Email : gwenaelle.delpirou@cegedim.com CSD CANADA OFFICES 4-2210 Markham Rd Toronto, ON M1B 5V6 CANADA 416-335-3545 CSD CANADA OFFICES 210-8250 boul. Décarie Montréal, QC H4P 2P5 CANADA 1-514-738-2771 59